Home - Chinese Journal of Cancer Research

2023 Impact Factor of CJCR: 7
Journal Citation Reports ™, Clarivate Analytics

National Health Commission guidelines for diagnosis and treatment of colorectal cancer 2023 in China (English version)

National Health Commission of the People’s Republic of China; Society of Oncology, Chinese Medical Association

Stomach cancer burden in China: Epidemiology and prevention

In 2020, stomach cancer was the fifth most commonly diagnosed cancer and the fourth leading cause of cancer-related death worldwide. Due to the relatively huge population base and the poor survival rate, stomach cancer is still a threat in China, and accounts for nearly half of the cases worldwide. Fortunately, in China, the incidence and mortality rates of stomach cancer presented a declining trend owing to the change of individual life styles and the persistent efforts to prevent stomach cancer from the governments at all levels. Helicobacter pylori (H. pylori) infection, poor eating habits, smoking, history of gastrointestinal disorders, and family history of stomach cancer are the main risk factors for stomach cancer in China. As a result, by taking risk factors for stomach cancer into account, specific preventive measures, such as eradicating H. pylori and implementing stomach cancer screening projects, should be taken to better prevent and decrease the burden of stomach cancer.

Burden of liver cancer: From epidemiology to prevention

In this review, we offer a concise overview of liver cancer epidemiology in China and worldwide from the official databases of GLOBOCAN 2020 and the National Cancer Registry in China. We also summarized the evidence for the main risk factors associated with liver cancer risk and discuss strategies implemented in China to control the liver cancer burden. Overall, liver cancer was the sixth most commonly diagnosed cancer and the third leading cause of cancer-related death worldwide in 2020. Although China contributed to nearly half of cases across the world alone, the incidence and mortality rates of liver cancer presented a declining trend owing to the persistent efforts from the governments at all levels. The current liver cancer burden in China still faces an arduous challenge due to the relatively large population base as well as the substantially low survival rate (12.1%). To better control the liver cancer burden with the lowest cost, specific measures should be conducted by reducing exposure to established risk factors such as hepatitis B infection and aflatoxin.

‹ ›

Vol 36, No 3 (June 2024)

CSCO Guidelines

CSCO guidelines for colorectal cancer version 2024: Updates and discussions

Liubo Chen, Hanguang Hu, Ying Yuan, Shanshan Weng

Pages: 233-239 HTML

Consensus and Expert Recommendation

Evidence-based expert consensus on clinical management of safety of Bruton’s tyrosine kinase inhibitors (2024)

Zaiwei Song, Dan Jiang, Lingling Yu, Yixuan Chen, Daobin Zhou, Yue Li, Depei Wu, Lingli Zhang, Liyan Miao, Jun Ma, Jun Zhu, Hongmei Jing, Rongsheng Zhao, on behalf of the Steering Committee, the Consensus Panel and the Evidence Synthesis Group; Evidence-based Pharmacy Professional Committee of Chinese Pharmaceutical Association (CPA), Hospital Pharmacy Professional Committee of Chinese Pharmaceutical Association (CPA), Division of Therapeutic Drug Monitoring of Chinese Pharmacological Society (CPS), Expert Committee on Lymphoma of Chinese Society of Clinical Oncology (CSCO), Expert Committee on Leukemia of Chinese Society of Clinical Oncology (CSCO), Society of Integrative Cardio-Oncology of China Anti-Cancer Association (CACA), Chinese Society of Hematology of Chinese Medical Association (CMA), Hospital Pharmacy Professional Committee of Cross-Straits Medicine Exchange Association (SMEA)

Pages: 240-256 HTML

Original Article

Tislelizumab in previously treated, locally advanced unresectable/metastatic microsatellite instability-high/mismatch repair-deficient solid tumors

Jian Li, Ye Xu, Aimin Zang, Yunong Gao, Quanli Gao, Yanqiao Zhang, Dong Wang, Jianming Xu, Ying Yuan, Haiping Jiang, Jieer Ying, Chunmei Shi, Yanhong Deng, Jing Wang, Tianshu Liu, Yi Huang, Xiaoping Qian, Yueyin Pan, Ying Cheng, Sheng Hu, Jin Wang, Mengyue Shi, Ke Wang, Han Hu, Lin Shen

Pages: 257-269 HTML

Effectiveness and safety of combined nimotuzumab and S-1 chemotherapy with concurrent radiotherapy for locally advanced esophageal cancer in malnourished and elderly patients: A prospective phase II study

Guojie Feng, Jiao Li, Nuo Yu, Ziyu Zheng, Xiongtao Yang, Lei Deng, Tao Zhang, Wenqing Wang, Wenyang Liu, Jianyang Wang, Qinfu Feng, Jima Lyu, Zefen Xiao, Zongmei Zhou, Nan Bi, Jianjun Qin, Xin Wang

Pages: 270-281 HTML

Clinical and molecular significance of homologous recombination deficiency positive non-small cell lung cancer in Chinese population: An integrated genomic and transcriptional analysis

Yifei Wang, Yidan Ma, Lei He, Jun Du, Xiaoguang Li, Peng Jiao, Xiaonan Wu, Xiaomao Xu, Wei Zhou, Li Yang, Jing Di, Changbin Zhu, Liming Xu, Tianlin Sun, Lin Li, Dongge Liu, Zheng Wang

Pages: 282-297 HTML

Nucleotide excision repair gene polymorphisms and hepatoblastoma susceptibility in Eastern Chinese children: A five-center case-control study

Huimin Yin, Xianqiang Wang, Shouhua Zhang, Shaohua He, Wenli Zhang, Hongting Lu, Yizhen Wang, Jing He, Chunlei Zhou

Pages: 298-305 HTML

Review Article

Mechanisms of resistance to trastuzumab in HER2-positive gastric cancer

Zhifei Li, Huan Zhao, Huihui Hu, Haili Shang, Yongjing Ren, Wenhui Qiu, Hao Su, Huifang Lyu, Xiaobing Chen

Pages: 306-321 HTML

Unlocking epigenetics for precision treatment of Ewing’s sarcoma

Zhehao Fan, Shuangshuang Dong, Ning Wang, Muhammad Babar Khawar, Jingcheng Wang, Haibo Sun

Pages: 322-340 HTML

Brief Communication

Unraveling links between aging, circadian rhythm and cancer: Insights from evidence-based analysis

Dechao Feng, Yuhan Xiao, Jie Wang, Ruicheng Wu, Zhouting Tuo, Koo Han Yoo, Wuran Wei, Dilinaer Wusiman, Zhipeng Wang, Dengxiong Li, Yubo Yang, William C. Cho, Mang Ke

Pages: 341-350 HTML

NHCPRC Guidelines

National Health Commission guidelines for diagnosis and treatment of colorectal cancer 2023 in China (English version)

National Health Commission of the People’s Republic of China; Society of Oncology, Chinese Medical Association

Pages: 197-232 HTML